TP53 and acute myeloid leukemia: In contrast, the new 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias recognizes “AML with mutated TP53” as a distinct disease category owing to its association with distinctly aggressive disease, complex cytogenetic abnormalities and very poor outcome.21